Will FedEx’s Spinoff Boost Its Stock Price?
In a pre-holiday surprise announcement, management at FedEx (NYSE:FDX) released…
Buy
51
PHGE Quote, Financials, Valuation and Earnings
Last price:
$0.69
Seasonality move
:
9.78%
Day range:
$0.65 - $0.78
52-week range:
$0.48 - $8.55
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.66x
Volume:
247.6K
Avg. volume:
94.4K
1-year change:
-75%
Market cap:
$12.7M
Revenue:
--
EPS (TTM):
-$4.00
Analysts' Opinion
-
Consensus RatingBiomX has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, BiomX has an estimated upside of 900.14% from its current price of $0.70.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $0.70.
Fair Value
-
According to the consensus of 0 analysts, BiomX has 900.14% upside to fair value with a price target of -- per share.
PHGE vs. S&P 500
-
Over the past 5 trading days, BiomX has overperformed the S&P 500 by 15.43% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
BiomX does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BiomX has grown year-over-year revenues for 0 quarters straight. In the most recent quarter BiomX reported revenues of --.
Earnings Growth
-
BiomX has grown year-over-year earnings for 0 quarters straight. In the most recent quarter BiomX reported earnings per share of $0.31.
Enterprise value:
7.8M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.21x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$31.4M | -$25.6M | -$32.3M | -$7.8M | -$10.5M | |
| EBITDA | -$28.1M | -$22.8M | -$6.2M | -$7.1M | $10M | |
| Diluted EPS | -$11.10 | -$6.50 | -$4.00 | -$1.30 | $0.31 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $65.3M | $69.8M | $42.5M | $25.3M | $28.3M | |
| Total Assets | $75.2M | $81.8M | $51.9M | $33.1M | $60M | |
| Current Liabilities | $4.7M | $9M | $7.5M | $12.8M | $8.9M | |
| Total Liabilities | $9.3M | $28.4M | $25.3M | $24.9M | $22.1M | |
| Total Equity | $65.8M | $53.4M | $26.6M | $8.2M | $37.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$31M | -$22.2M | -$36.9M | -$5.9M | -$8.1M | |
| Cash From Investing | -$3.7M | $3.4M | $710K | -$32K | -$1K | |
| Cash From Financing | $4.3M | $4.2M | $37.4M | -$1.3M | -- | |
| Free Cash Flow | -$31.2M | -$22.3M | -$37M | -$6M | -$8.1M | |
PHGE
Sector
Market Cap
$12.7M
$46.3M
Price % of 52-Week High
8.19%
46%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.64%
1-Year Price Total Return
-75%
-33.33%
Beta (5-Year)
1.314
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$0.62
200-day SMA
Sell
Level
$2.15
Bollinger Bands (100)
Sell
Level
0.61 - 1.29
Chaikin Money Flow
Buy
Level
4.4M
20-day SMA
Buy
Level
$0.64
Relative Strength Index (RSI14)
Buy
Level
54.29
ADX Line
Buy
Level
15.63
Williams %R
Neutral
Level
-35.3195
50-day SMA
Sell
Level
$0.70
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Buy
Level
92
On Balance Volume
Neutral
Level
39.5M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.
Stock Forecast FAQ
In the current month, PHGE has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PHGE average analyst price target in the past 3 months is --.
-
Where Will BiomX Stock Be In 1 Year?
According to analysts, the consensus estimate is that BiomX share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About BiomX?
Analysts are divided on their view about BiomX share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BiomX is a Sell and believe this share price will drop from its current level to --.
-
What Is BiomX's Price Target?
The price target for BiomX over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PHGE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BiomX is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of PHGE?
You can purchase shares of BiomX via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BiomX shares.
-
What Is The BiomX Share Price Today?
BiomX was last trading at $0.69 per share. This represents the most recent stock quote for BiomX. Yesterday, BiomX closed at $0.70 per share.
-
How To Buy BiomX Stock Online?
In order to purchase BiomX stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Buffett Buying Verisign?
Warren Buffett has spent 2024 stockpiling cash, even going so…
Is Microsoft an Undervalued Growth Stock to Buy?
Tech giant Microsoft (NASDAQ:MSFT) has been one of the biggest…
Stock Ideas
Buy
59
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 41x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Buy
100
IPX alert for Dec 31
IperionX [IPX] is up 15.26% over the past day.
Buy
58
QMCO alert for Dec 31
Quantum [QMCO] is down 11.99% over the past day.
Buy
80
PSIX alert for Dec 31
Power Solutions International [PSIX] is up 11.6% over the past day.
